Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3225760#aggregation> ?p ?o. }
Showing items 1 to 33 of
33
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B814555.
- aggregation creator B814556.
- aggregation creator B814557.
- aggregation creator B814558.
- aggregation creator person.
- aggregation date "2013".
- aggregation format "application/pdf".
- aggregation hasFormat 3225760.bibtex.
- aggregation hasFormat 3225760.csv.
- aggregation hasFormat 3225760.dc.
- aggregation hasFormat 3225760.didl.
- aggregation hasFormat 3225760.doc.
- aggregation hasFormat 3225760.json.
- aggregation hasFormat 3225760.mets.
- aggregation hasFormat 3225760.mods.
- aggregation hasFormat 3225760.rdf.
- aggregation hasFormat 3225760.ris.
- aggregation hasFormat 3225760.txt.
- aggregation hasFormat 3225760.xls.
- aggregation hasFormat 3225760.yaml.
- aggregation isPartOf urn:issn:1742-6405.
- aggregation language "eng".
- aggregation rights "I have retained and own the full copyright for this publication".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting".
- aggregation abstract "While the introduction of combination highly active antiretroviral therapy (HAART) regimens represents an important advance in the management of human immunodeficiency virus (HIV)-infected patients, tolerability can be an issue and the use of several different agents may produce problems. The switch of combination HAART to ritonavir-boosted protease inhibitor (PI) monotherapy may offer the opportunity to maintain antiviral efficacy while reducing treatment complexity and the risks of toxicity. Current European AIDS Clinical Society (EACS) guidelines recognise ritonavir-boosted PI monotherapy with twice-daily lopinavir/ritonavir or once-daily darunavir/ritonavir as a possible option in patients who have intolerance to nucleoside reverse transcriptase inhibitors, or for treatment simplification. Clinical trials data for PI boosted monotherapy are encouraging, showing substantial efficacy in the majority of patients; however, further data are required before this approach can be recommended as a routine treatment. Available data indicate that the most suitable candidates for the use of boosted PI monotherapy are long-term virologically suppressed patients who have demonstrated good adherence to antiretroviral therapy, who do not have chronic hepatitis B, have no history of treatment failure on PIs and are able to tolerate low-dose ritonavir.".
- aggregation authorList BK1187140.
- aggregation volume "10".
- aggregation aggregates 3225851.
- aggregation isDescribedBy 3225760.
- aggregation similarTo 1742-6405-10-3.
- aggregation similarTo LU-3225760.